Vogenx (NASDAQ:VOGX) Issues Earnings Results, Beats Expectations By $0.01 EPS

Vogenx (NASDAQ:VOGX) posted its earnings results on Friday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01, Zacks reports.

Vogenx Trading Down 4.3%

Shares of NASDAQ:VOGX traded down $0.78 during mid-day trading on Friday, reaching $17.45. The company had a trading volume of 66,333 shares, compared to its average volume of 147,027. The stock has a market capitalization of $259.13 million and a price-to-earnings ratio of -249.29. The company has a 50-day simple moving average of $23.77. Vogenx has a one year low of $12.95 and a one year high of $38.41.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. WBB Securities assumed coverage on Vogenx in a research note on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 price target for the company. Zacks Research upgraded Vogenx to a “hold” rating in a report on Monday, September 28th. Wall Street Zen raised Vogenx to a “hold” rating in a report on Saturday, August 22nd. Finally, JonesTrading initiated coverage on shares of Vogenx in a research report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $48.50.

Vogenx Company Profile

Vogenx, Inc is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company has historically concentrated on small-molecule drug candidates intended to address conditions in which existing treatment options may be limited.

Vogenx’s lead development program has included VGX-1027, an investigational anti-inflammatory compound studied for its potential to regulate abnormal immune responses. Research involving the candidate has focused on diseases associated with inflammation and immune-system dysfunction, although its development status and commercial availability may change over time.

The company’s activities have primarily involved pharmaceutical research and development rather than the marketing of an established portfolio of products.